Crystalline Forms Of N-[4-(Chlorodifluoromethoxy)Phenyl]-6-[(3R)-3-Hydroxypyrrolidin-1-Yl]-5-(1H-Pyrazol-5-Yl)Pyridine-3-Carboxamide
Patent No. EP3969117 (titled "Crystalline Forms Of N-[4-(Chlorodifluoromethoxy)Phenyl]-6-[(3R)-3-Hydroxypyrrolidin-1-Yl]-5-(1H-Pyrazol-5-Yl)Pyridine-3-Carboxamide") was filed by Novartis on May 15, 2020. The application was issued on Mar 25, 2026.
Patent Summary
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
EP3969117
- Application Number
- EP20726959A
- Filing Date
- May 15, 2020
- Status
- Granted And Under Opposition
- Feb 20, 2026
- Publication Date
- Mar 25, 2026
- External Links
- Slate, Register , Google Patents